Initiatives to enhance renin–angiotensin prescribing efficiency in Austria: impact and implications for other countries

References

• Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson LL. Enhancing the rational use of new medicines across European healthcare systems – a position paper. Eur. J. Clin. Pharmacol.64, 1137–1138 (2008).
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, Hoffman M et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev. Pharmacoeconomics Outcomes Res.9(1), 65–83 (2009).
   PubMedGoogle Scholar
• Comma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan Region: impact and future direction. Expert Rev. Pharmacoeconomics Outcomes Res.9(6), 569–581 (2009).
   PubMedGoogle Scholar
• Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France; implications for key stakeholder groups. Appl. Health Econ. Health Policy8, 7–24 (2010).
   PubMedGoogle Scholar
• Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid lowering drugs. Pharmacoeconomics27, 435–438 (2009).
   PubMed Web of Science ®Google Scholar
• Godman B, Haycox A, Schwabe U et al. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics26, 91–98 (2008).
   PubMed Web of Science ®Google Scholar
• Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V. Recent national and regional drug reforms in Sweden – implications for pharmaceutical companies in Europe. Pharmacoeconomics26, 537–550 (2008).
   PubMed Web of Science ®Google Scholar
• Godman B, Bucsics A, Burkhardt T et al. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoeconomics Outcomes Res.8(4), 357–371 (2008).
   PubMedGoogle Scholar
• Godman B, Burkhardt T, Bucsics A et al. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid lowering drugs: implications for the future. Expert Rev. Pharmacoeconomics Outcomes Res.9(5), 475–484 (2009).
   PubMedGoogle Scholar
• McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A. Initiatives to enhance the efficiency of statin and proton pump inhibitor prescribing in the UK; impact and implications Expert Rev. Pharmacoeconomics Outcomes Res.10(1), 73–85 (2010).
   PubMed Web of Science ®Google Scholar
• Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking – an overview of current approaches and their consequences. Appl. Health Econ. Health Policy7(3), 1–11 (2009).
   PubMedGoogle Scholar
• Leal J, Luengo-Fernandez R, Gray A et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur. Heart J.27, 1610–1619 (2006).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens. Res.28, 385–407 (2005).
   PubMed Web of Science ®Google Scholar
• Gradman A. Evolving the understanding of the renin–angiotensin–aldosterone system: pathophysiology and targets for therapeutic intervention. Am. Heart J.157, S1–S6 (2009).
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-R et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens27, 2121–2158 (2009).
   PubMed Web of Science ®Google Scholar
• Matcher D, McCroy D, Orlando L et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin I receptor blockers for treating essential hypertension. Ann. Intern. Med.148, 16–29 (2008).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Carlberg B, Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet366, 1545–1553 (2005).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care27, S65–S67 (2004).
   PubMedGoogle Scholar
• Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension42, 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Frisk P, Mellgren T-O, Hedberg N et al. Utilization of angiotensin blockers in Sweden combining survey and register data to study adherence to prescribing guidelines. Eur. J. Clin. Pharmacol.64, 1223–1229 (2008).
   PubMed Web of Science ®Google Scholar
• Dickstein K, Cohen-Solal A, Filippatos G et al.; on behalf of the task force for the Diagnosis and Treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur. Heart J.29, 2388–2442 (2008).
   PubMed Web of Science ®Google Scholar
• Gradman A, Papademetriou V. Combined renin–angiotensin–aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction. Am. Heart J.157, S17–S23 (2009).
   PubMed Web of Science ®Google Scholar
• Mielniczuk L, Stevenson L. Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in the management of congestive heart failure patients: what have we learnt from recent clinical trials. Curr. Opin. Cardiol.20, 250–255 (2005).
   PubMed Web of Science ®Google Scholar
• Strippoli G, Craig M, Schena F et al. Role of blood pressure targets and specific antihypertensive agents used to prevent diabeteic nephropathy and delay its progression. J. Am. Soc. Nephrol.17, S153–S155 (2006).
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL et al.; for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med.359, 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Fletcher A, Palmer A, Bulpitt C. Coughing with angiotensin converting enzyme inhibitors; how much of a problem? J. Hypertens.12, S43–S47 (1994).
   Google Scholar
• Elliot H. Focus on the ONTARGET results. J. Hypertens.27, S8–S10 (2009).
   Google Scholar
• McDowell S, Coleman J, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine BMJ332, 1177–1181 (2006).
   PubMed Web of Science ®Google Scholar
• Walley T, Folino-Gallo P, Schwabe U, van Ganse E; on behalf of the EuroMedStat group. Variations and increase use of statins across Europe: data from administrative databases. BMJ328, 385–386 (2004).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Benedict A, Muszabek N et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int. J. Clin. Pract.62, 76–87 (2008).
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, Messerli F. Fixed-dose combinations improve medication compliance: a meta analysis. Am. J. Med.120, 713–719 (2007).
   PubMed Web of Science ®Google Scholar
• Garattini L, Ghislandi S. Off-patent drugs in Italy: a short sighted view? Eur. J. Health Econ.7, 79–83 (2006).
   PubMedGoogle Scholar
• Wettermark B, Pehrsson A, Juhasz-Haverinen M et al. Financial incentives linked to self-assessment of prescribing patterns – a new approach for quality improvement of drug prescribing in primary care. Qual. Prim. Care17, 179–189 (2009).
   PubMedGoogle Scholar
• Wettermark B, Godman B, Neovius M et al. Initial effects of a reimbursement restriction to improve the cost–effectiveness of antihypertensive treatment. Health Policy94, 221–229 (2010).
   PubMed Web of Science ®Google Scholar
• Schnneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy81, 17–28 (2007).
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Walker A, Glynn R et al. Outcome of reference pricing for angiotensin-converting-enzyme inhibitors. N. Engl. J. Med.346, 822–829 (2002).
   PubMed Web of Science ®Google Scholar
• Araszkiewicz AA, Szabert K, Godman B, Wladysiuk M, Barbui C, Haycox A. Generic olanzapine: health authority opportunity or nightmare? Expert Rev. Pharmacoeconomics Outcomes Res.8(6), 549–555 (2008).
   PubMedGoogle Scholar
• Wladysiuk M, Araszkiewicz A, Godman B et al. Patient co-payments do influence atypical antipsychotic choice in Poland; implications once generic atypcials are available. Appl. Health Econ. Health Policy (2010) (In Press).
   Google Scholar
• Sakshaug S, Furu K, Karlstead O et al. Switching statins in Norway after new reimbursement policy – a nationwide prescription study. Br. J. Clin. Pharmacol.64, 476–481 (2007).
   PubMed Web of Science ®Google Scholar
• Fretheim A, Håvelsrud K, MacLennan G et al. The effects of mandatory prescribing of thiazides for newly treated, uncomplicated hypertension: interrupted time-series analysis. PLoS Med.e232, 1178–1186 (2007).
   Google Scholar
• Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patient’s care. Lancet362, 1225–1230 (2003).
   PubMed Web of Science ®Google Scholar
• Bero LA, Grilli R, Grimshaw JM et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ317, 465–468 (1998).
   PubMed Web of Science ®Google Scholar